Goldbars, don't fret over Sabretoothed. He/she has a plonker on Quadrant for some reason. The petulant pussycat didn't like it at 4c and still doesn't like QAD now - though the story is still advancing nicely.
But that's fine. The timeframe on a value stock like this is always going to burn off traders who think one month is a long time to be invested!
Interesting that the proposed acquisition, the data and kiosk business from Healthpoint Technologies Ltd, is already profitable with an established brand and sales channel. The synergy it has with the ATM-like Remote Dispensing Machines (for after-hours dispensing at pharmacies) that Quadrant already has its foot on, is evident.
What I like to see is Boyd diversifying QAD into the healthcare area – an area in which he has a proven track record (and then some!). And always with prudent, carefully cost-controlled additions.
Quadrant’s 10% holding in Iridium remains an unrecognised asset. However, even there, I’d expect some movement before too much longer.
Meanwhile, the ETSdirect and Approach businesses are both growing strongly. And with Friday’s announcement of increased exposure to the European arm of the enterprise, earnings should grow apace.
Yes, I’m very sanguine about this one. Give it time.
QAD
quadrant iridium limited
